Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRIT: SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy in High-Risk Rectal Adenocarcinoma
NCT06908031Phase 2Completed
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
A Phase 2 trial of PD-1 Monoclonal Antibody, cetuximab, bevacizumab in rectal adenocarcinoma, sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Started Apr 2025; status: completed.
02
Drugs
PD-1 Monoclonal Antibodycetuximabbevacizumab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT06908031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06908031.